STARNCT04068753
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 32 words
- Primary completion date changed from estimate of Dec 2026 to Aug 6, 2026
- Study completion date: Jul 2027 to Aug 2027
- Notable Primary completion date: Dec 2025 to Dec 2026v20
- Minor Primary completion date: Sep 2025 to Dec 2025v19
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 4 of 4 sites
- Minor Primary completion date: Jul 2025 to Sep 2025v17
Show 15 earlier versionsHide 15 earlier versions
- Minor Site details revised at 1 of 4 sitesv16
- Minor Site details revised at 1 of 4 sitesv15
- Notable Primary completion date: Jul 2024 to Jul 2025
- Study completion date: Jul 2026 to Jul 2027
- Notable Eligibility criteria expanded, about 157 words
- Site details revised at 1 of 4 sites
- Notable Primary completion date: Jul 2023 to Jul 2024
- Study completion date: Jul 2025 to Jul 2026
- Minor Study sites revised (4)v11
- Minor Site details revised at 1 of 4 sitesv10
- Minor Site details revised at 1 of 4 sitesv9
- Minor Site details revised at 2 of 4 sitesv8
- Notable Primary completion date: Jul 2021 to Jul 2023v7
- Minor Study sites: 3 to 4v6
- Minor Site contacts updated at 1 of 3 sitesv5
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
- Study sites: 1 to 3
- Primary completion date: Jun 2021 to Jul 2021
- Study completion date: Jun 2025 to Jul 2025
- Start date changed from estimate of Feb 2020 to Feb 26, 2020
- Minor Study description shortened, about 18 wordsv3
Notable Start date: Sep 2019 to Feb 2020v2 Show 6 more changesShow less
- Eligibility criteria revised
- Study completion date: Dec 2024 to Jun 2025
- Interventions: Niraparib (Drug), TSR-042 (Drug) to Niraparib (Drug), dostarlimab (Drug)
- Secondary endpoints: details revised at 4 of 4 entries
- Study description revised
- Study title revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients with response to treatment
Timeframe: 1 year
Secondary (4)
Number of patients who experience toxicity
Duration of patients with response
Progression free survival
Overall survival
Arms and interventions
Niraparib + dostarlimabExperimental
Drugs: Niraparib, dostarlimab
Sites
4 sites in 1 country